Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Broad Institute

JULY 26, 2022

Learn more Drug Repurposing Hub A curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds. Learn more PRISM Rapid, high-throughput multiplexed compound screening in genomically characterized human cancer cell-line models.

Compound Screening 52

Compound Screening FDA Approval Engineering RNA 52

The ChEMBL-og

APRIL 16, 2024

See [link] and INN clinical candidate drugs (assigned as max_phase = 2 based on INN guidance that states “As a general guide, the development of a drug should progress up to the point of clinical trials (phase II) before an application is submitted to the INN Secretariat for name selection.” See [link] Pref_name curation.

Clinical Trials 110

Clinical Trials FDA Cell Based Assays Compound Screening 110